ATE440863T1 - Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion - Google Patents

Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion

Info

Publication number
ATE440863T1
ATE440863T1 AT98946057T AT98946057T ATE440863T1 AT E440863 T1 ATE440863 T1 AT E440863T1 AT 98946057 T AT98946057 T AT 98946057T AT 98946057 T AT98946057 T AT 98946057T AT E440863 T1 ATE440863 T1 AT E440863T1
Authority
AT
Austria
Prior art keywords
variants
derivatives
chemokine
analogues
inhibiting
Prior art date
Application number
AT98946057T
Other languages
English (en)
Inventor
David Grainger
Lauren Tatalick
Suzanne Kanaly
Original Assignee
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd filed Critical Cambridge Entpr Ltd
Application granted granted Critical
Publication of ATE440863T1 publication Critical patent/ATE440863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98946057T 1997-09-11 1998-09-11 Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion ATE440863T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/927,939 US6989435B2 (en) 1997-09-11 1997-09-11 Compounds and methods to inhibit or augment an inflammatory response
PCT/US1998/019052 WO1999012968A2 (en) 1997-09-11 1998-09-11 Chemokine peptides, variants, derivatives and analogs, their use in methods to inhibit or augment an inflammatory response

Publications (1)

Publication Number Publication Date
ATE440863T1 true ATE440863T1 (de) 2009-09-15

Family

ID=25455479

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946057T ATE440863T1 (de) 1997-09-11 1998-09-11 Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion

Country Status (9)

Country Link
US (2) US6989435B2 (de)
EP (1) EP1012187B1 (de)
JP (1) JP4523151B2 (de)
AT (1) ATE440863T1 (de)
AU (1) AU9315398A (de)
CA (1) CA2303422A1 (de)
DE (1) DE69841105D1 (de)
ES (1) ES2332616T3 (de)
WO (1) WO1999012968A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP2386565A3 (de) * 1999-01-12 2013-11-20 Cambridge Enterprise Ltd. Verbindungen und Verfahren zur Hemmung oder Verstärkung einer Entzündungsreaktion
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7208152B2 (en) 1999-11-24 2007-04-24 Millennium Pharmaceuticals, Inc. Antibodies for “Bonzo” chemokine receptor and therapeutic uses thereof
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
US20030087274A1 (en) * 2001-07-05 2003-05-08 Anderson David W. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030077247A1 (en) * 2001-09-20 2003-04-24 Schering Corporation Chemokines as adjuvants of immune response
WO2003077947A1 (en) * 2002-03-15 2003-09-25 Schering Corporation Methods of modulating cd200 receptors
WO2005053702A2 (en) 2003-12-01 2005-06-16 Cambridge University Technical Services Limited Anti-inflammatory agents
CA2548917C (en) * 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US8137397B2 (en) * 2004-02-26 2012-03-20 Boston Scientific Scimed, Inc. Medical devices
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
WO2006074179A2 (en) * 2005-01-04 2006-07-13 University Of Rochester Blockade of elr+cxc chemokines as a treatment for inflammatory and autoimmune disease
US20060247760A1 (en) * 2005-04-29 2006-11-02 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysms adjacent branch arteries
CA2649253A1 (en) * 2005-05-25 2006-11-30 Hadasit Medical Research Services & Development Ltd. Cxcr4 antagonists for wound healing and re-epithelialization
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
WO2007021807A1 (en) 2005-08-12 2007-02-22 Schering Corporation Mcp1 fusions
EP1989326A4 (de) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex-verfolgungstest
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
CA2694454A1 (en) * 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
ES2342810B1 (es) 2008-09-10 2011-07-05 Pere Poch Marti Abrebocas perfeccionado para la introduccion de mascarillas laringeasy otros dispositivos medicos a traves de la cavidad oral.
WO2010082177A2 (en) 2009-01-16 2010-07-22 Sederma New compounds, in particular peptides, compositions comprising them and cosmetic and dermopharmaceutical uses
FR2941231B1 (fr) 2009-01-16 2016-04-01 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
FR2941232B1 (fr) 2009-01-16 2014-08-08 Sederma Sa Nouveaux peptides, compositions les comprenant et utilisations cosmetiques et dermo-pharmaceutiques.
EP2421561A2 (de) * 2009-04-21 2012-02-29 Selecta Biosciences, Inc. Immunnanotherapeutika für th1-biased response
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
EP2575773A4 (de) 2010-05-26 2014-06-25 Selecta Biosciences Inc Synthetische nanoträgerkombinationsimpfstoffe
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
US20140045211A1 (en) * 2011-03-24 2014-02-13 The Regents Of The University Of California High level production of recombinant proteins
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US9962428B2 (en) * 2012-12-21 2018-05-08 National University Corporation Nagoya University Composition having tissue-repairing activity, and use therefor
ITRM20130199A1 (it) 2013-04-03 2014-10-04 Irbm Science Park S P A Peptidi per uso dermatologico e/o cosmetico
EP3478321A4 (de) 2016-06-30 2020-04-22 Oncorus, Inc. Pseudotypisierte onkolytische virale verabreichung von therapeutischen polypeptiden
WO2019133847A1 (en) * 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2740788A (en) * 1956-04-03 J-hydroxy-n-propargyl-morphinanes
US2726243A (en) * 1954-01-08 1955-12-06 Ciba Pharm Prod Inc Hydrazides of yohimbic acid
US2743270A (en) * 1954-05-26 1956-04-24 Univ Michigan Heterocyclic nitrogen compounds
FR2135087B1 (de) 1971-05-06 1974-08-23 Serdex
FR2229403B2 (de) 1973-05-18 1976-08-13 Serdex Etud Rech Diffusion Ex
FR2239471A1 (en) 1973-08-03 1975-02-28 Omnium Chimique Sa Corynanthine hydrazides - as therapeutic agents
HU172479B (hu) 1976-03-09 1978-09-28 Gyogyszerkutato Intezet Sposob poluchenija novykh soedinenij s ehrgolenovymi i
US4737580A (en) 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US5248666A (en) 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
WO1986004334A1 (en) 1985-01-18 1986-07-31 MERCK Patent Gesellschaft mit beschränkter Haftung Immunoregulatory peptides
JPS62501502A (ja) * 1985-01-18 1987-06-18 イミユーンテツク・フアーマシユーテイカルズ 免疫調節性ペプチド
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US4774318A (en) 1985-11-22 1988-09-27 Oncogen Snake venom growth arresting peptide
JPH01503513A (ja) 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
US5827821A (en) 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5202118A (en) 1987-12-18 1993-04-13 Immunex Corporation Method for promoting wound healing using IL-1
DE68925032T2 (de) 1988-08-15 1996-04-25 Brigham & Womens Hospital Leukozyten-adhäsions-inhibitor.
IL92938A (en) 1989-01-01 1998-08-16 Us Commerce A polypeptide that has a mutagenic activity on monocytes and AND that encodes it
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US5484885A (en) 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
IL95500A (en) 1989-09-11 1997-03-18 Matrix Pharma ANTI-PROLIFERATIVE COMPOSITIONS CONTAINING TGF-b PROTEIN IN A VISCOUS MATRIX AND THEIR USE
WO1991008483A1 (en) 1989-11-29 1991-06-13 Brigham And Women's Hospital Endothelial-derived il-8
US5661132A (en) 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5079228A (en) 1990-02-05 1992-01-07 Board Of Regents, The University Of Texas System Peptide inhibitors of neutrophil activating factor induced chemotaxis
US5190918A (en) 1990-02-22 1993-03-02 W. R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin and methods of use
US5155038A (en) 1990-02-22 1992-10-13 W. R. Grace & Co.-Conn. Use of thrombospondin to promote wound healing
US5190920A (en) 1990-09-24 1993-03-02 W. R. Grace & Co.-Conn. Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity
CA2041271A1 (en) 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IE913192A1 (en) 1990-09-12 1992-02-25 Scripps Research Inst Active site of interleukin-8: polypeptide analogs and¹antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5824647A (en) 1990-12-12 1998-10-20 Postlethwaite; Arnold E. Chemotactic wound healing peptides
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
CA2111870A1 (en) 1991-06-21 1993-01-07 Robert W. Colman Calpain-inhibiting peptide analogs of the kininogen heavy chain
US5401651A (en) 1991-10-16 1995-03-28 Walz; Alfred DNA encoding ENA-78, a neutrophil activating factor
US5707814A (en) 1991-11-01 1998-01-13 The Regents Of The University Of California CD8+ cell antiviral factor
US5326752A (en) 1991-11-27 1994-07-05 Glycomed Incorporated Substituted lactose and lactosamine derivatives as cell adhesion inhibitors
DE69226649D1 (de) 1991-12-04 1998-09-17 Biomedical Research Centre Ltd Analoge des menschlichen Interleukin-8.
US5357041A (en) 1991-12-06 1994-10-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin
JPH0625288A (ja) 1992-07-10 1994-02-01 Kuraray Co Ltd ペプチドまたはその塩
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
WO1994009128A1 (en) 1992-10-22 1994-04-28 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
US5807884A (en) 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
ATE179712T1 (de) 1993-03-01 1999-05-15 Glycan Pharm Inc Analoge für spezifische oligosaccharid-protein- wechselwirkungen und ihre verwendungen
US5627265A (en) 1993-03-05 1997-05-06 Washington University Receptor for cell-binding domain of thrombospondins
US5474983A (en) 1993-03-15 1995-12-12 The Research Foundation Of State University Of New York Method of inhibiting pro-inflammatory mediator release from basophils and mast cells
JP3623985B2 (ja) 1993-05-31 2005-02-23 財団法人化学及血清療法研究所 抗ｌｄ７８ポリペプチドモノクローン抗体
JPH09505555A (ja) 1993-08-13 1997-06-03 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシーズ ＴＧＦ−βの活性を刺激および阻害する方法および組成物
JPH0782169A (ja) 1993-09-13 1995-03-28 Toray Ind Inc 創傷治療剤
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
US5578714A (en) 1993-10-21 1996-11-26 New York Blood Center, Inc. DNA encoding Duffy 9pd protein
US5459128A (en) 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
AU1398595A (en) 1993-12-22 1995-07-10 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the factor ixa platelet binding site
WO1995017420A1 (en) 1993-12-22 1995-06-29 Temple University - Of The Commonwealth System Of Higher Education Peptide analogs of the activated platelet binding site on factor xi
WO1995019436A1 (en) 1994-01-13 1995-07-20 The Regents Of The University Of California Mammalian monocyte chemoattractant protein receptors
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
GB9406492D0 (en) 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
GB9406463D0 (en) 1994-03-31 1994-05-25 Medical Res Council Cervical ripening
US5627156A (en) 1994-09-23 1997-05-06 University Of Nebraska Board Of Regents Polypeptide agonists for human interleukin-8
US5877276A (en) 1994-09-23 1999-03-02 The Board Of Regents Of The University Of Nebraska Polypeptide agonists for human interleukin-8
US5684032A (en) 1994-12-13 1997-11-04 Smithkline Beecham Corporation Compounds
WO1996020722A1 (en) 1995-01-03 1996-07-11 Thomas Jefferson University Compounds that inhibit t cell proliferation and methods using the same
US5645837A (en) 1995-01-17 1997-07-08 Thomas Jefferson University Peptides that inhibit T cell activation and methods of using the same
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
WO1996025157A1 (en) 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
US5955485A (en) 1995-02-23 1999-09-21 Janssen Pharmaceutica, N.V. Use of fused benzothiazoles as neuroprotectants
AU5528996A (en) 1995-03-22 1996-10-08 Eli Lilly And Company Methods of treating or preventing pain or nociception
US5817911A (en) 1995-04-07 1998-10-06 Regents Of The University Of California Transgenic mice expressing alveolar MCP-1
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
CA2226017A1 (en) 1995-06-29 1997-01-16 Thomas Jefferson University Cd4-derived peptides that inhibit immune responses
GB9518611D0 (en) 1995-09-12 1995-11-15 Ludwig Inst Cancer Res Anti-apoptotic factors
ES2233978T3 (es) 1995-09-27 2005-06-16 SHIONOGI & CO., LTD. Proteina analoga a la quimiocina de tipo cc.
JPH11514861A (ja) 1995-09-29 1999-12-21 イミュネックス・コーポレーション ケモカインインヒビター
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ZA969721B (en) 1995-11-21 1997-11-28 Smithkline Beecham Corp Method of treating sepsis.
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
WO1997025427A1 (en) 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
AU2246597A (en) 1996-02-12 1997-08-28 Schering Corporation Mammalian dendritic cell chemokine reagents
AU5355996A (en) 1996-02-23 1997-09-10 Human Genome Sciences, Inc. Human chemokine polypeptides
DE69739366D1 (de) 1996-03-01 2009-05-28 Euroscreen Sa Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren
JPH09255570A (ja) 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
EP1021181A4 (de) 1996-03-28 2002-06-26 Smithkline Beecham Corp Indolcarbonsäuren als chemokin-inhibitoren
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
GB2319252A (en) 1996-11-08 1998-05-20 Diapharm Limited Polypeptides involved in the interaction of HIV gp120 with the fusin, and the CC-CKR-5 co-receptors thereof
US5700821A (en) 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
US6274342B1 (en) 1996-09-18 2001-08-14 Center For Blood Research, Inc. Nucleic acid molecules encoding monocyte chemotactic protein 5 (MCP-5) molecules and uses therefor
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
JP3614610B2 (ja) 1997-05-02 2005-01-26 新日鉄ソリューションズ株式会社 メール送信システム、メール送信方法及び記録媒体
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP0906954A1 (de) 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
CA2335588A1 (en) 1998-06-29 2000-01-06 Edwin F. Ullman Assay for homocysteine
US7238711B1 (en) * 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2001014886A2 (en) * 1999-08-23 2001-03-01 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium

Also Published As

Publication number Publication date
US20010006640A1 (en) 2001-07-05
AU9315398A (en) 1999-03-29
EP1012187A2 (de) 2000-06-28
JP4523151B2 (ja) 2010-08-11
US20060073114A1 (en) 2006-04-06
US7700087B2 (en) 2010-04-20
EP1012187B1 (de) 2009-08-26
WO1999012968A2 (en) 1999-03-18
JP2001515918A (ja) 2001-09-25
WO1999012968A3 (en) 1999-07-29
CA2303422A1 (en) 1999-03-18
DE69841105D1 (de) 2009-10-08
US6989435B2 (en) 2006-01-24
ES2332616T3 (es) 2010-02-09

Similar Documents

Publication Publication Date Title
ATE440863T1 (de) Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhíhung von einer entzündungsreaktion
MX9804263A (es) Expresion de genes incrementada por intensificador en plantas.
FI962247A (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
NZ333128A (en) Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I
ES2107033T3 (es) Peptidos bpc, su preparacion y su utilizacion.
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
BR9811592A (pt) Oxidase de citocinina
DK2256205T3 (da) Porphorymonas gingivalis-polypeptider og -polynukleotider
ATE196926T1 (de) Gen grb3-3, variante und ihre verwendungen
NO964022L (no) -2-antichymotrypsinanaloger med elastasehemmende aktivitet
BR0312889A (pt) Polipeptìdeo t20 peguilado
ATE192490T1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
DK0544826T3 (da) Overlegne trombomodulinanaloger til farmaceutisk anvendelse
ATE517912T1 (de) Protein, das an der wiederherstellung der fruchtbarkeit nach cytoplasmischer männlicher sterilität beteiligt ist, und ein dieses codierendes gen
DE69526087D1 (de) Or-1, ein wais-rezeptor der nuklearen rezeptoren familie
ATE89005T1 (de) Rekombinantes vektorsystem fuer metalloproteinase- inhibitorsequenz und dessen verwendung und herstellung nach dem rekombinant-dns-verfahren.
PT90739A (pt) Processo para a preparacao de uma proteina dotada de actividade de inibicao de trombina
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
ATE452903T1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ES2127516T3 (es) Peptidos para inhibir la liberacion de pepsina.
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.
WO1999060117A3 (fr) Polypeptide prax-1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties